Verdicts genuinely change. Free email alert the moment XBI's does — no target price to set, unlike "Alert" above.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
State Street(R) SPDR(R) S&P(R) Biotech ETF ETF · SPDR SERIES TRUST
161 holdings · as of 2026-06-30 (3.5 months ago) The fund may have traded since. SEC Form N-PORT is filed quarterly and lags the period it covers, so these are the most recent holdings on file, not the fund’s holdings today.
This fund holds short positions, so exposure is counted gross — long and short both count as exposure rather than netting off, and the weights below therefore sum to 106% of net assets rather than 100%. Shares of the portfolio are shown as shares of that gross exposure.
NON-COMPLIANT At least 29.03% of portfolio weight is in non-compliant holdings — already over the 5% threshold, so the verdict is settled whatever the unmatched 48% turns out to be. Matching more holdings can only raise this share, never lower it.
161 holdings, 93 matched (55% of weight). Portfolio as of 2026-06-30, filed 2026-08-28. Source: SEC Form N-PORT.
13.64% of this portfolio’s income is non-permissible — weighted across holdings, computed over 41% of portfolio weight (65 of 161 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
Portfolio shares are withheld: coverage is below the floor needed to state one. The holdings themselves are below, because the names are evidence you can check.
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| State Street Global Advisors | UNSCREENED | 5.87% | no in-house ratios for this holding |
| Apogee Therapeutics Inc | UNSCREENED | 1.49% | no in-house ratios for this holding |
| MRNA Moderna Inc | NON_COMPLIANT | 1.41% | AAOIFI2.2% Usmani11.7% Dow Jones Islamic7.4% S&P Shariah5.1% MSCI Islamic11.4% MSCI Islamic M-Series5.1% FTSE Shariah5.4% |
| TWST Twist Bioscience Corp | COMPLIANT | 1.41% | AAOIFI1.1% Usmani13.9% Dow Jones Islamic3.2% S&P Shariah3.5% MSCI Islamic13.9% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| Oruka Therapeutics Inc | UNSCREENED | 1.38% | no in-house ratios for this holding |
| KYMR Kymera Therapeutics Inc | NON_COMPLIANT | 1.36% | AAOIFI0.8% Usmani4.8% Dow Jones Islamic1.7% S&P Shariah2.1% MSCI Islamic4.6% MSCI Islamic M-Series2.1% FTSE Shariah0.0% |
| Viking Therapeutics Inc | UNSCREENED | 1.30% | no in-house ratios for this holding |
| Praxis Precision Medicines Inc | UNSCREENED | 1.29% | no in-house ratios for this holding |
| Erasca Inc | UNSCREENED | 1.27% | no in-house ratios for this holding |
| Revolution Medicines Inc | UNSCREENED | 1.20% | no in-house ratios for this holding |
| RYTM Rhythm Pharmaceuticals Inc | NON_COMPLIANT | 1.20% | AAOIFI1.6% Usmani25.1% Dow Jones Islamic2.0% S&P Shariah2.5% MSCI Islamic25.1% MSCI Islamic M-Series2.5% FTSE Shariah24.3% |
| CG oncology Inc | UNSCREENED | 1.20% | no in-house ratios for this holding |
| SELLAS Life Sciences Group Inc | UNSCREENED | 1.19% | no in-house ratios for this holding |
| Vaxcyte Inc | UNSCREENED | 1.19% | no in-house ratios for this holding |
| Dianthus Therapeutics Inc | UNSCREENED | 1.18% | no in-house ratios for this holding |
| CYTK Cytokinetics Inc | NON_COMPLIANT | 1.18% | AAOIFI3.9% Usmani20.7% Dow Jones Islamic5.9% S&P Shariah6.2% MSCI Islamic20.7% MSCI Islamic M-Series6.2% FTSE Shariah14.3% |
| NTRA Natera Inc | COMPLIANT | 1.16% | AAOIFI0.5% Usmani9.0% Dow Jones Islamic0.9% S&P Shariah1.2% MSCI Islamic9.0% MSCI Islamic M-Series1.2% FTSE Shariah3.0% |
| Scholar Rock Holding Corp | UNSCREENED | 1.16% | no in-house ratios for this holding |
| Roivant Sciences Ltd | UNSCREENED | 1.16% | no in-house ratios for this holding |
| MIRM Mirum Pharmaceuticals Inc | COMPLIANT | 1.16% | AAOIFI11.6% Usmani73.0% Dow Jones Islamic20.3% S&P Shariah25.7% MSCI Islamic73.0% MSCI Islamic M-Series25.7% FTSE Shariah71.8% |
| Cogent Biosciences Inc | UNSCREENED | 1.14% | no in-house ratios for this holding |
| RARE Ultragenyx Pharmaceutical Inc | NON_COMPLIANT | 1.14% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| TVTX Travere Therapeutics Inc | COMPLIANT | 1.13% | AAOIFI10.0% Usmani77.2% Dow Jones Islamic24.4% S&P Shariah32.6% MSCI Islamic77.2% MSCI Islamic M-Series32.6% FTSE Shariah75.4% |
| ALKS Alkermes PLC | COMPLIANT | 1.11% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| KRYS Krystal Biotech Inc | NON_COMPLIANT | 1.10% | AAOIFI0.1% Usmani0.6% Dow Jones Islamic0.1% S&P Shariah0.2% MSCI Islamic0.6% MSCI Islamic M-Series0.2% FTSE Shariah0.0% |
| Celcuity Inc | UNSCREENED | 1.10% | no in-house ratios for this holding |
| Relay Therapeutics Inc | UNSCREENED | 1.10% | no in-house ratios for this holding |
| Spyre Therapeutics Inc | UNSCREENED | 1.10% | no in-house ratios for this holding |
| TGTX TG Therapeutics Inc | COMPLIANT | 1.09% | AAOIFI8.8% Usmani46.0% Dow Jones Islamic13.7% S&P Shariah17.0% MSCI Islamic46.0% MSCI Islamic M-Series17.0% FTSE Shariah45.5% |
| BEAM Beam Therapeutics Inc | NON_COMPLIANT | 1.08% | AAOIFI8.2% Usmani17.8% Dow Jones Islamic10.4% S&P Shariah10.7% MSCI Islamic17.8% MSCI Islamic M-Series10.7% FTSE Shariah7.2% |
| Insmed Inc | UNSCREENED | 1.08% | no in-house ratios for this holding |
| PTGX Protagonist Therapeutics Inc | NON_COMPLIANT | 1.07% | AAOIFI0.1% Usmani1.0% Dow Jones Islamic0.2% S&P Shariah0.3% MSCI Islamic1.0% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| ARWR Arrowhead Pharmaceuticals Inc | COMPLIANT | 1.07% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Vera Therapeutics Inc | UNSCREENED | 1.06% | no in-house ratios for this holding |
| VRTX Vertex Pharmaceuticals Inc | COMPLIANT | 1.06% | AAOIFI1.6% Usmani7.2% Dow Jones Islamic1.7% S&P Shariah1.7% MSCI Islamic7.2% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| MDGL Madrigal Pharmaceuticals Inc | COMPLIANT | 1.06% | AAOIFI2.8% Usmani27.9% Dow Jones Islamic3.8% S&P Shariah4.6% MSCI Islamic27.9% MSCI Islamic M-Series4.6% FTSE Shariah27.4% |
| ABBV AbbVie Inc | COMPLIANT | 1.04% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| BIIB Biogen Inc | COMPLIANT | 1.03% | AAOIFI21.2% Usmani22.5% Dow Jones Islamic27.5% S&P Shariah24.3% MSCI Islamic22.5% MSCI Islamic M-Series24.3% FTSE Shariah21.3% |
| PTCT PTC Therapeutics Inc | NON_COMPLIANT | 1.03% | AAOIFI11.9% Usmani21.4% Dow Jones Islamic16.9% S&P Shariah20.0% MSCI Islamic21.2% MSCI Islamic M-Series20.0% FTSE Shariah18.2% |
| HALO Halozyme Therapeutics Inc | COMPLIANT | 1.03% | AAOIFI17.2% Usmani83.3% Dow Jones Islamic27.4% S&P Shariah30.4% MSCI Islamic83.3% MSCI Islamic M-Series30.4% FTSE Shariah83.3% |
| uniQure NV | UNSCREENED | 1.03% | no in-house ratios for this holding |
| BBIO Bridgebio Pharma Inc | COMPLIANT | 1.02% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| CRSP CRISPR Therapeutics AG | NON_COMPLIANT | 1.02% | AAOIFI15.5% Usmani29.6% Dow Jones Islamic17.0% S&P Shariah16.8% MSCI Islamic29.6% MSCI Islamic M-Series16.8% FTSE Shariah22.1% |
| ImmunityBio Inc | UNSCREENED | 1.02% | no in-house ratios for this holding |
| Summit Therapeutics Inc | UNSCREENED | 1.01% | no in-house ratios for this holding |
| IONS Ionis Pharmaceuticals Inc | NON_COMPLIANT | 1.00% | AAOIFI21.0% Usmani67.5% Dow Jones Islamic23.0% S&P Shariah25.1% MSCI Islamic67.5% MSCI Islamic M-Series25.1% FTSE Shariah58.8% |
| INCY Incyte Corp | COMPLIANT | 1.00% | AAOIFI0.1% Usmani0.7% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.3% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| AMGN Amgen Inc | COMPLIANT | 0.99% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| NBIX Neurocrine Biosciences Inc | COMPLIANT | 0.97% | AAOIFI2.9% Usmani8.6% Dow Jones Islamic3.4% S&P Shariah3.5% MSCI Islamic8.6% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| GILD Gilead Sciences Inc | COMPLIANT | 0.96% | AAOIFI14.4% Usmani53.2% Dow Jones Islamic18.6% S&P Shariah21.4% MSCI Islamic53.2% MSCI Islamic M-Series21.4% FTSE Shariah53.2% |
| REGN Regeneron Pharmaceuticals Inc | COMPLIANT | 0.96% | AAOIFI2.4% Usmani6.5% Dow Jones Islamic3.0% S&P Shariah2.7% MSCI Islamic4.8% MSCI Islamic M-Series2.7% FTSE Shariah4.8% |
| EXEL Exelixis Inc | COMPLIANT | 0.96% | AAOIFI1.2% Usmani6.7% Dow Jones Islamic1.5% S&P Shariah1.7% MSCI Islamic6.7% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| ALNY Alnylam Pharmaceuticals Inc | COMPLIANT | 0.96% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| BMRN BioMarin Pharmaceutical Inc | NON_COMPLIANT | 0.94% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ACAD ACADIA Pharmaceuticals Inc | COMPLIANT | 0.94% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| Nuvalent Inc | UNSCREENED | 0.93% | no in-house ratios for this holding |
| Immunovant Inc | UNSCREENED | 0.92% | no in-house ratios for this holding |
| UTHR United Therapeutics Corp | NON_COMPLIANT | 0.92% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| NTLA Intellia Therapeutics Inc | NON_COMPLIANT | 0.91% | AAOIFI4.1% Usmani8.6% Dow Jones Islamic5.1% S&P Shariah4.1% MSCI Islamic8.6% MSCI Islamic M-Series4.1% FTSE Shariah0.0% |
| GRAL GRAIL Inc | NON_COMPLIANT | 0.91% | AAOIFI2.5% Usmani3.2% Dow Jones Islamic4.7% S&P Shariahfail MSCI Islamic3.2% MSCI Islamic M-Seriesfail FTSE Shariah0.0% |
| BioCryst Pharmaceuticals Inc | UNSCREENED | 0.89% | no in-house ratios for this holding |
| Catalyst Pharmaceuticals Inc | UNSCREENED | 0.87% | no in-house ratios for this holding |
| Dyne Therapeutics Inc | UNSCREENED | 0.86% | no in-house ratios for this holding |
| TNGX Tango Therapeutics Inc | NON_COMPLIANT | 0.84% | AAOIFI0.8% Usmani3.0% Dow Jones Islamic2.2% S&P Shariah2.5% MSCI Islamic3.0% MSCI Islamic M-Series2.5% FTSE Shariah0.0% |
| Denali Therapeutics Inc | UNSCREENED | 0.83% | no in-house ratios for this holding |
| VCYT Veracyte Inc | COMPLIANT | 0.82% | AAOIFI1.1% Usmani2.7% Dow Jones Islamic1.4% S&P Shariah1.6% MSCI Islamic2.7% MSCI Islamic M-Series1.6% FTSE Shariah0.0% |
| IDYA Ideaya Biosciences Inc | NON_COMPLIANT | 0.80% | AAOIFI0.8% Usmani2.2% Dow Jones Islamic1.2% S&P Shariah1.1% MSCI Islamic2.2% MSCI Islamic M-Series1.1% FTSE Shariah0.0% |
| RXRX Recursion Pharmaceuticals Inc | NON_COMPLIANT | 0.76% | AAOIFI3.4% Usmani5.5% Dow Jones Islamic7.3% S&P Shariah6.1% MSCI Islamic5.5% MSCI Islamic M-Series6.1% FTSE Shariah1.2% |
| Sarepta Therapeutics Inc | UNSCREENED | 0.75% | no in-house ratios for this holding |
| RCUS Arcus Biosciences Inc | COMPLIANT | 0.74% | AAOIFI3.0% Usmani12.3% Dow Jones Islamic5.9% S&P Shariah6.5% MSCI Islamic12.3% MSCI Islamic M-Series6.5% FTSE Shariah10.9% |
| Syndax Pharmaceuticals Inc | UNSCREENED | 0.72% | no in-house ratios for this holding |
| ARQT Arcutis Biotherapeutics Inc | COMPLIANT | 0.71% | AAOIFI3.8% Usmani23.4% Dow Jones Islamic5.0% S&P Shariah6.5% MSCI Islamic23.4% MSCI Islamic M-Series6.5% FTSE Shariah22.3% |
| Mineralys Therapeutics Inc | UNSCREENED | 0.71% | no in-house ratios for this holding |
| Celldex Therapeutics Inc | UNSCREENED | 0.70% | no in-house ratios for this holding |
| AGIO Agios Pharmaceuticals Inc | NON_COMPLIANT | 0.69% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Viridian Therapeutics Inc | UNSCREENED | 0.67% | no in-house ratios for this holding |
| NVAX Novavax Inc | NON_COMPLIANT | 0.66% | AAOIFI17.3% Usmani31.1% Dow Jones Islamic21.2% S&P Shariah22.9% MSCI Islamic30.5% MSCI Islamic M-Series22.9% FTSE Shariah30.5% |
| Disc Medicine Inc | UNSCREENED | 0.65% | no in-house ratios for this holding |
| ADMA ADMA Biologics Inc | COMPLIANT | 0.61% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahpass |
| IMNM Immunome Inc | NON_COMPLIANT | 0.59% | AAOIFI0.2% Usmani0.8% Dow Jones Islamic0.3% S&P Shariah0.4% MSCI Islamic0.8% MSCI Islamic M-Series0.4% FTSE Shariah0.0% |
| Palvella Therapeutics Inc | UNSCREENED | 0.58% | no in-house ratios for this holding |
| IOVA Iovance Biotherapeutics Inc | COMPLIANT | 0.56% | AAOIFI1.2% Usmani5.0% Dow Jones Islamic2.9% S&P Shariah2.4% MSCI Islamic5.0% MSCI Islamic M-Series2.4% FTSE Shariah0.0% |
| ABSI Absci Corp | COMPLIANT | 0.56% | AAOIFI— Usmanifail Dow Jones Islamicfail S&P Shariah— MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| NRIX Nurix Therapeutics Inc | NON_COMPLIANT | 0.56% | AAOIFI2.1% Usmani10.9% Dow Jones Islamic4.1% S&P Shariah5.0% MSCI Islamic10.9% MSCI Islamic M-Series5.0% FTSE Shariah0.0% |
| Kodiak Sciences Inc | UNSCREENED | 0.54% | no in-house ratios for this holding |
| Biohaven Ltd | UNSCREENED | 0.53% | no in-house ratios for this holding |
| VCEL Vericel Corp | COMPLIANT | 0.49% | AAOIFI4.0% Usmani18.5% Dow Jones Islamic4.4% S&P Shariah4.4% MSCI Islamic18.4% MSCI Islamic M-Series4.4% FTSE Shariah0.0% |
| AnaptysBio Inc | UNSCREENED | 0.49% | no in-house ratios for this holding |
| Capricor Therapeutics Inc | UNSCREENED | 0.49% | no in-house ratios for this holding |
| STOK Stoke Therapeutics Inc | NON_COMPLIANT | 0.48% | AAOIFI0.1% Usmani0.7% Dow Jones Islamic0.2% S&P Shariah0.3% MSCI Islamic0.7% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| GLUE Monte Rosa Therapeutics Inc | NON_COMPLIANT | 0.48% | AAOIFI4.3% Usmani5.5% Dow Jones Islamic4.5% S&P Shariah5.9% MSCI Islamic5.5% MSCI Islamic M-Series5.9% FTSE Shariah0.0% |
| VIR Vir Biotechnology Inc | NON_COMPLIANT | 0.47% | AAOIFI6.1% Usmani7.7% Dow Jones Islamic8.6% S&P Shariah8.1% MSCI Islamic7.7% MSCI Islamic M-Series8.1% FTSE Shariah0.0% |
| PURR Hyperliquid Strategies Inc | NON_COMPLIANT | 0.46% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| TYRA Tyra Biosciences Inc | COMPLIANT | 0.41% | AAOIFI0.3% Usmani1.5% Dow Jones Islamic0.5% S&P Shariah0.6% MSCI Islamic1.5% MSCI Islamic M-Series0.6% FTSE Shariah0.0% |
| CRVS Corvus Pharmaceuticals Inc | COMPLIANT | 0.41% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Cullinan Therapeutics Inc | UNSCREENED | 0.40% | no in-house ratios for this holding |
| PGEN Precigen Inc | NON_COMPLIANT | 0.38% | AAOIFI3.9% Usmani57.7% Dow Jones Islamic9.9% S&P Shariah12.7% MSCI Islamic57.7% MSCI Islamic M-Series12.7% FTSE Shariah55.1% |
| Inhibrx Biosciences Inc | UNSCREENED | 0.35% | no in-house ratios for this holding |
| TSHA Taysha Gene Therapies Inc | NON_COMPLIANT | 0.35% | AAOIFI3.1% Usmani12.1% Dow Jones Islamic5.9% S&P Shariah7.4% MSCI Islamic12.0% MSCI Islamic M-Series7.4% FTSE Shariah10.5% |
| ARDX Ardelyx Inc | COMPLIANT | 0.35% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Avalo Therapeutics Inc | UNSCREENED | 0.35% | no in-house ratios for this holding |
| MNKD MannKind Corp | NON_COMPLIANT | 0.34% | AAOIFI26.0% Usmani45.2% Dow Jones Islamic22.7% S&P Shariah24.3% MSCI Islamic45.2% MSCI Islamic M-Series24.3% FTSE Shariah43.6% |
| ANNX Annexon Inc | COMPLIANT | 0.33% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ORIC ORIC Pharmaceuticals Inc | COMPLIANT | 0.33% | AAOIFI0.3% Usmani0.8% Dow Jones Islamic0.4% S&P Shariah0.4% MSCI Islamic0.8% MSCI Islamic M-Series0.4% FTSE Shariah0.0% |
| ZBIO Zenas Biopharma Inc | NON_COMPLIANT | 0.32% | AAOIFI3.9% Usmani11.3% Dow Jones Islamic8.0% S&P Shariah— MSCI Islamic11.3% MSCI Islamic M-Series— FTSE Shariah11.2% |
| JBIO Jade Biosciences Inc | NON_COMPLIANT | 0.32% | AAOIFI0.0% Usmani0.1% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.1% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| Kura Oncology Inc | UNSCREENED | 0.32% | no in-house ratios for this holding |
| OLMA Olema Pharmaceuticals Inc | NON_COMPLIANT | 0.32% | AAOIFI0.1% Usmani0.1% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.1% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| CDNA CareDx Inc | COMPLIANT | 0.30% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Bicara Therapeutics Inc | UNSCREENED | 0.30% | no in-house ratios for this holding |
| VOR Vor BioPharma Inc | NON_COMPLIANT | 0.30% | AAOIFI0.3% Usmani0.6% Dow Jones Islamic0.9% S&P Shariah1.2% MSCI Islamic0.6% MSCI Islamic M-Series1.2% FTSE Shariah0.0% |
| Xencor Inc | UNSCREENED | 0.29% | no in-house ratios for this holding |
| ArriVent Biopharma Inc | UNSCREENED | 0.28% | no in-house ratios for this holding |
| Replimune Group Inc | UNSCREENED | 0.28% | no in-house ratios for this holding |
| CTMX CytomX Therapeutics Inc | NON_COMPLIANT | 0.28% | AAOIFI0.7% Usmani1.5% Dow Jones Islamic1.3% S&P Shariah1.8% MSCI Islamic1.5% MSCI Islamic M-Series1.8% FTSE Shariah0.0% |
| JANX Janux Therapeutics Inc | NON_COMPLIANT | 0.28% | AAOIFI1.7% Usmani2.1% Dow Jones Islamic1.4% S&P Shariah1.4% MSCI Islamic2.1% MSCI Islamic M-Series1.4% FTSE Shariah0.0% |
| Sionna Therapeutics Inc | UNSCREENED | 0.27% | no in-house ratios for this holding |
| Geron Corp | UNSCREENED | 0.26% | no in-house ratios for this holding |
| Solid Biosciences Inc | UNSCREENED | 0.24% | no in-house ratios for this holding |
| RIGL Rigel Pharmaceuticals Inc | COMPLIANT | 0.24% | AAOIFI5.0% Usmani8.8% Dow Jones Islamic9.0% S&P Shariah11.3% MSCI Islamic8.8% MSCI Islamic M-Series11.3% FTSE Shariah8.6% |
| Allogene Therapeutics Inc | UNSCREENED | 0.24% | no in-house ratios for this holding |
| Sana Biotechnology Inc | UNSCREENED | 0.23% | no in-house ratios for this holding |
| Altimmune Inc | UNSCREENED | 0.23% | no in-house ratios for this holding |
| RGNX REGENXBIO Inc | NON_COMPLIANT | 0.22% | AAOIFI11.7% Usmani17.8% Dow Jones Islamic14.0% S&P Shariah12.0% MSCI Islamic17.8% MSCI Islamic M-Series12.0% FTSE Shariah0.0% |
| IRWD Ironwood Pharmaceuticals Inc | NON_COMPLIANT | 0.22% | AAOIFI30.0% Usmani74.1% Dow Jones Islamic45.1% S&P Shariah27.1% MSCI Islamic74.1% MSCI Islamic M-Series27.1% FTSE Shariah70.0% |
| IMMX Immix Biopharma Inc | NON_COMPLIANT | 0.20% | AAOIFI0.1% Usmani0.4% Dow Jones Islamic0.4% S&P Shariah0.5% MSCI Islamic0.4% MSCI Islamic M-Series0.5% FTSE Shariah0.0% |
| OCGN Ocugen Inc | NON_COMPLIANT | 0.20% | AAOIFI1.2% Usmani4.5% Dow Jones Islamic1.5% S&P Shariah1.7% MSCI Islamic4.5% MSCI Islamic M-Series1.7% FTSE Shariah1.4% |
| FDMT 4D Molecular Therapeutics Inc | NON_COMPLIANT | 0.20% | AAOIFI4.7% Usmani8.0% Dow Jones Islamic9.8% S&P Shariah6.8% MSCI Islamic8.0% MSCI Islamic M-Series6.8% FTSE Shariah4.0% |
| Candel Therapeutics Inc | UNSCREENED | 0.19% | no in-house ratios for this holding |
| SVRA Savara Inc | NON_COMPLIANT | 0.18% | AAOIFI2.7% Usmani15.7% Dow Jones Islamic3.9% S&P Shariah4.2% MSCI Islamic15.7% MSCI Islamic M-Series4.2% FTSE Shariah15.7% |
| PRME Prime Medicine Inc | NON_COMPLIANT | 0.18% | AAOIFI16.8% Usmani45.2% Dow Jones Islamic21.9% S&P Shariah18.8% MSCI Islamic45.2% MSCI Islamic M-Series18.8% FTSE Shariah0.0% |
| First Tracks Biotherapeutics Inc | UNSCREENED | 0.17% | no in-house ratios for this holding |
| DMRA Damora Therapeutics Inc | NON_COMPLIANT | 0.17% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| SPRY ARS Pharmaceuticals Inc | NON_COMPLIANT | 0.17% | AAOIFI17.3% Usmani38.7% Dow Jones Islamic8.7% S&P Shariah9.8% MSCI Islamic38.7% MSCI Islamic M-Series9.8% FTSE Shariah38.7% |
| MPLT MapLight Therapeutics Inc | NON_COMPLIANT | 0.17% | AAOIFI0.3% Usmani0.5% Dow Jones Islamic— S&P Shariah— MSCI Islamic0.5% MSCI Islamic M-Series— FTSE Shariah0.0% |
| ABUS Arbutus Biopharma Corp | NON_COMPLIANT | 0.16% | AAOIFI0.1% Usmani0.2% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.2% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| MYGN Myriad Genetics Inc | NON_COMPLIANT | 0.16% | AAOIFI69.0% Usmani32.9% Dow Jones Islamic25.9% S&P Shariah18.2% MSCI Islamic32.9% MSCI Islamic M-Series18.2% FTSE Shariah18.9% |
| Cabaletta Bio Inc | UNSCREENED | 0.15% | no in-house ratios for this holding |
| Compass Therapeutics Inc | UNSCREENED | 0.14% | no in-house ratios for this holding |
| EBS Emergent BioSolutions Inc | NON_COMPLIANT | 0.13% | AAOIFI184.7% Usmani52.7% Dow Jones Islamic132.4% S&P Shariah158.7% MSCI Islamic52.7% MSCI Islamic M-Series158.7% FTSE Shariah52.1% |
| PRTA Prothena Corp PLC | NON_COMPLIANT | 0.13% | AAOIFI1.4% Usmani2.3% Dow Jones Islamic1.2% S&P Shariah0.8% MSCI Islamic2.3% MSCI Islamic M-Series0.8% FTSE Shariah0.0% |
| VNDA Vanda Pharmaceuticals Inc | NON_COMPLIANT | 0.13% | AAOIFI5.1% Usmani5.5% Dow Jones Islamic4.9% S&P Shariah5.2% MSCI Islamic3.8% MSCI Islamic M-Series5.2% FTSE Shariah0.0% |
| CATX Perspective Therapeutics Inc | NON_COMPLIANT | 0.13% | AAOIFI1.1% Usmani1.0% Dow Jones Islamic1.1% S&P Shariah1.0% MSCI Islamic1.0% MSCI Islamic M-Series1.0% FTSE Shariah0.4% |
| OVID Ovid therapeutics Inc | NON_COMPLIANT | 0.12% | AAOIFI2.3% Usmani5.5% Dow Jones Islamic8.0% S&P Shariah7.3% MSCI Islamic5.5% MSCI Islamic M-Series7.3% FTSE Shariah0.0% |
| VSTM Verastem Inc | NON_COMPLIANT | 0.12% | AAOIFI6.3% Usmani16.1% Dow Jones Islamic8.5% S&P Shariah10.1% MSCI Islamic16.1% MSCI Islamic M-Series10.1% FTSE Shariah14.8% |
| MDXG MiMedx Group Inc | COMPLIANT | 0.11% | AAOIFI2.5% Usmani6.1% Dow Jones Islamic1.9% S&P Shariah1.8% MSCI Islamic6.1% MSCI Islamic M-Series1.8% FTSE Shariah6.1% |
| Lexeo Therapeutics Inc | UNSCREENED | 0.11% | no in-house ratios for this holding |
| Achieve Life Sciences Inc | UNSCREENED | 0.08% | no in-house ratios for this holding |
| SGMT Sagimet Biosciences Inc | NON_COMPLIANT | 0.07% | AAOIFI0.3% Usmani0.7% Dow Jones Islamic1.0% S&P Shariah1.2% MSCI Islamic0.7% MSCI Islamic M-Series1.2% FTSE Shariah0.0% |
| CONTRA METSERA INC | UNSCREENED | 0.07% | no in-house ratios for this holding |
| BridgeBio Oncology Therapeutics Inc | UNSCREENED | 0.06% | no in-house ratios for this holding |
| State Street Global Advisors | UNSCREENED | 0.04% | no in-house ratios for this holding |
| CONTRA AKERO THERAPEUT | UNSCREENED | 0.01% | no in-house ratios for this holding |
| CONTRA INHIBRX INC | UNSCREENED | 0.01% | no in-house ratios for this holding |
| CONTRA MIRATI THERAPEU | UNSCREENED | 0.01% | no in-house ratios for this holding |
| CONTRA VERVE THERAPEUT | UNSCREENED | 0.01% | no in-house ratios for this holding |
| CONTRA BLUEPRINT MEDIC | UNSCREENED | 0.00% | no in-house ratios for this holding |
| State Street Global Advisors | UNSCREENED | 0.00% | no in-house ratios for this holding |
| RNA Atrium Therapeutics Inc | NON_COMPLIANT | 0.00% | AAOIFI0.7% Usmani0.6% Dow Jones Islamic— S&P Shariah— MSCI Islamic0.6% MSCI Islamic M-Series— FTSE Shariah0.0% |
| OABI OMNIAB INC | NON_COMPLIANT | 0.00% | AAOIFI3.0% Usmani6.5% Dow Jones Islamic5.9% S&P Shariah4.7% MSCI Islamic6.5% MSCI Islamic M-Series4.7% FTSE Shariah0.0% |
| OABI OMNIAB INC | NON_COMPLIANT | 0.00% | AAOIFI3.0% Usmani6.5% Dow Jones Islamic5.9% S&P Shariah4.7% MSCI Islamic6.5% MSCI Islamic M-Series4.7% FTSE Shariah0.0% |
The published standards disagree about this fund by 19 points of portfolio weight — 25.0% of it passes AAOIFI, 6.0% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 25.0% ratios fail on 22.0% 58.8% not rated under AAOIFI
ratios pass on 10.8% ratios fail on 36.8% 58.3% not rated under Usmani
ratios pass on 22.8% ratios fail on 24.1% 58.9% not rated under Dow Jones Islamic
ratios pass on 23.1% ratios fail on 22.1% 60.7% not rated under S&P Shariah
ratios pass on 6.0% ratios fail on 43.4% 56.5% not rated under MSCI Islamic
ratios pass on 23.1% ratios fail on 22.7% 60.2% not rated under MSCI Islamic M-Series
ratios pass on 10.9% ratios fail on 36.2% 58.7% not rated under FTSE Shariah
92 of 161 listed holdings carry our own per-methodology verdicts (58% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 77 (47% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| MRNA Moderna Inc | 1.41% |
| KYMR Kymera Therapeutics Inc | 1.36% |
| RYTM Rhythm Pharmaceuticals Inc | 1.20% |
| CYTK Cytokinetics Inc | 1.18% |
| RARE Ultragenyx Pharmaceutical Inc | 1.14% |
| KRYS Krystal Biotech Inc | 1.10% |
| BEAM Beam Therapeutics Inc | 1.08% |
| PTGX Protagonist Therapeutics Inc | 1.07% |
| PTCT PTC Therapeutics Inc | 1.03% |
| CRSP CRISPR Therapeutics AG | 1.02% |
Methodology breakdown computing — it will appear here on its own.
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
State Street(R) SPDR(R) S&P(R) Biotech ETF (XBI) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
Computing the full ratio and business-activity breakdown for XBI — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 37.10 | NEUTRAL |
| Stochastic %K (14) | 12.02 | BUY |
| CCI (20) | -164.02 | BUY |
| Williams %R (14) | -87.98 | BUY |
| MACD (12,26,9) | -0.74 | SELL |
| ROC (10) | -6.75 | SELL |
| Momentum (10) | -10.65 | SELL |
| EMA (10) | 151.07 | SELL |
| SMA (10) | 151.45 | SELL |
| EMA (20) | 153.43 | SELL |
| SMA (20) | 154.35 | SELL |
| EMA (30) | 154.66 | SELL |
| SMA (30) | 156.02 | SELL |
| EMA (50) | 154.96 | SELL |
| SMA (50) | 158.24 | SELL |
| EMA (100) | 151.04 | SELL |
| SMA (100) | 152.15 | SELL |
| EMA (200) | 140.47 | BUY |
| SMA (200) | 139.84 | BUY |
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 42 |
| ⏰ 4H | BEARISH | 51 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Still fetching insider filings — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-06 · Asset managers net 906615 (+2612)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.